Skip to content

Research for percutaneous transluminal angioplasty (PTA)-related restenosis via NLRP3-mediated pyroptosis of endothelial cells in diabetic lower extremity vessels

Research for percutaneous transluminal angioplasty (PTA)-related restenosis via NLRP3-mediated pyroptosis of endothelial cells in diabetic lower extremity vessels

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029677
Enrollment
Unknown
Registered
2020-02-09
Start date
2020-02-10
Completion date
Unknown
Last updated
2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriosclerosis obliterans(ASO)

Interventions

Case series:N/A

Sponsors

Affiliated Hospital of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >= 25 years old; 2. it was in accordance with the diagnostic criteria of diabetic angiopathy or lower extremity angiopathy: 1) Routine examination: ECG and echocardiography can understand the cardiac function, and confirm whether there is coronary atherosclerosis leading to myocardial ischemia; 2) Color Doppler ultrasonography: it can show the local arterial lesions well. Such as the shape of lumen, atherosclerotic plaque, blood flow status, etc. CTA is the most accurate examination method, which can determine the location of artery calcification and show irregular calcification spots in abdominal aorta or lower extremity artery; 3. arteriography and digital subtraction angiography: not only can clearly show the shape of artery, but also can understand the size and length of calcified plaque in detail; 4. it has PTA operation indication of lower extremity vascular disease.

Exclusion criteria

Exclusion criteria: 1. Combined with malignant tumor; 2. combined with serious gastrointestinal diseases (including peptic ulcer, hepatitis, inflammatory bowel disease, intestinal tuberculosis, severe diarrhea, constipation, etc.); 3. serious cardiac insufficiency; 4. combined with various non diabetic nephropathy; 5. combined with infection, fever, rheumatic immune diseases in the near future; 6. life expectancy less than 12 months or other compliance that may lead to program non-compliance Complications; 7. aged > 85 years old; 8. uncooperative.

Design outcomes

Primary

MeasureTime frame
IL-1beta;hs-CRP;

Countries

China

Contacts

Public ContactXiaolei Sun

Affiliated Hospital of Southwest Medical University

sunxiaolei_lg@163.com+86 13688209071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026